Literature DB >> 22143330

Nondialysis chronic kidney disease in 2011: Progression, prediction, populations and possibilities.

Adeera Levin1.   

Abstract

In 2011, studies of chronic kidney disease (CKD) were published in abundance. The articles selected here represent the growing appreciation of the importance of CKD as a modifier of outcomes, breakthroughs in understanding the pathobiology and genetics of specific conditions, and clinical trials of treatment strategies that offer hope to patients with CKD.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22143330     DOI： 10.1038/nrneph.2011.195

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

2.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

3.  A predictive model for progression of chronic kidney disease to kidney failure.

Authors:  Navdeep Tangri; Lesley A Stevens; John Griffith; Hocine Tighiouart; Ognjenka Djurdjev; David Naimark; Adeera Levin; Andrew S Levey
Journal:  JAMA       Date:  2011-04-11       Impact factor: 56.272

4.  Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.

Authors:  Carmen A Peralta; Michael G Shlipak; Suzanne Judd; Mary Cushman; William McClellan; Neil A Zakai; Monika M Safford; Xiao Zhang; Paul Muntner; David Warnock
Journal:  JAMA       Date:  2011-04-11       Impact factor: 56.272

5.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Authors:  Changli Wei; Shafic El Hindi; Jing Li; Alessia Fornoni; Nelson Goes; Junichiro Sageshima; Dony Maiguel; S Ananth Karumanchi; Hui-Kim Yap; Moin Saleem; Qingyin Zhang; Boris Nikolic; Abanti Chaudhuri; Pirouz Daftarian; Eduardo Salido; Armando Torres; Moro Salifu; Minnie M Sarwal; Franz Schaefer; Christian Morath; Vedat Schwenger; Martin Zeier; Vineet Gupta; David Roth; Maria Pia Rastaldi; George Burke; Phillip Ruiz; Jochen Reiser
Journal:  Nat Med       Date:  2011-07-31       Impact factor: 53.440

6.  GFR decline and mortality risk among patients with chronic kidney disease.

Authors:  Robert M Perkins; Ion D Bucaloiu; H Lester Kirchner; Nasrin Ashouian; James E Hartle; Taher Yahya
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-16       Impact factor: 8.237

7.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.

Authors:  Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2010-12-08       Impact factor: 10.612

8.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

9.  Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

Authors:  Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Jackson Wright; Larry Appel; Tom Greene; Adeera Levin; Ognjenka Djurdjev; David C Wheeler; Martin J Landray; John N Townend; Jonathan Emberson; Laura E Clark; Alison Macleod; Angharad Marks; Tariq Ali; Nicholas Fluck; Gordon Prescott; David H Smith; Jessica R Weinstein; Eric S Johnson; Micah L Thorp; Jack F Wetzels; P J Blankestijn; A D van Zuilen; Vandana Menon; Mark Sarnak; Gerald Beck; Florian Kronenberg; Barbara Kollerits; Marc Froissart; Benedicte Stengel; Marie Metzger; Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; H J Lambers Heerspink; Barry Brenner; Dick de Zeeuw; Peter Rossing; Hans-Henrik Parving; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

10.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321
  10 in total
  1 in total

1.  Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease.

Authors:  Manabu Shibasaki; Jian-Guo Wang; Jose-Luiz Figueiredo; Sophie E P New; Thibaut Quillard; Claudia Goettsch; Jun-ichiro Koga; Hiroyuki Sonoki; Jiro Matsumoto; Masanori Aikawa; Elena Aikawa
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.